An observational study in Thoracic Cancer, Gynecologic Cancer and Abdomen Tumors, sponsored by The Affiliated Hospital of Qingdao University. Status unknown at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-05-29.
Sponsored by The Affiliated Hospital of Qingdao University · Observational
Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.
Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's planned enrollment of 500 is above the median of 182 across 438 observational studies indexed under Melanoma.
Browse Melanoma studies →The Affiliated Hospital of Qingdao University is the lead sponsor of 142 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients treated with PD-1 agents (nivolumab, pebrolizumab, toripalimab, sintilimab)
Exclusion Criteria:
Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
Drug: Chemotherapy
Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
Drug: Chemotherapy
Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
Drug: Chemotherapy
Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
Drug: Chemotherapy
compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
Also known as: targeting therapy
Overall Response Rate (ORR)
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters). The percentage of strongly PD-L1 positive participants who experienced a CR or PR is presented.
Time frame: 1 year
Number of Participants Experiencing Adverse Events (AEs)
Adverse events are defined as any adverse medical events that occur in the participants taking the drugs and do not necessarily have a causal relationship with the treatment.
Time frame: 1 year
PFS
PFS was defined as the time from the first day of study treatment to the first documented disease progression per irRC or death due to any cause, whichever occurred first.
Time frame: 2 years
Plan to share: No — IPD only shared in the study group
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of Qingdao University